Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan:150:103350.
doi: 10.1016/j.jaut.2024.103350. Epub 2024 Dec 18.

Advances in chimeric antigen receptor T cell therapy for autoimmune and autoinflammatory diseases and their complications

Affiliations
Review

Advances in chimeric antigen receptor T cell therapy for autoimmune and autoinflammatory diseases and their complications

Liuting Zeng et al. J Autoimmun. 2025 Jan.

Abstract

Chimeric antigen receptor T (CAR-T) cells are genetically engineered T cells expressing transmembrane chimeric antigen receptors with specific targeting abilities. As an emerging immunotherapy, the use of CAR-T cells has made significant breakthroughs in cancer treatment, particularly for hematological malignancies. The success of CAR-T cell therapy in blood cancers highlights its potential for other conditions in which the clearance of pathological cells is therapeutic, such as liver diseases, infectious diseases, heart failure, and diabetes. Given the limitations of current therapies for autoimmune diseases, researchers have actively explored the potential therapeutic value of CAR-T cells and their derivatives in the field of autoimmune diseases. This review focuses on the research progress and current challenges of CAR-T cells in autoimmune diseases with the aim of providing a theoretical basis for the precise treatment of autoimmune diseases. In the future, CAR-T cells may present new therapeutic modalities and ultimately provide hope for patients with autoimmune diseases.

Keywords: Autoimmune diseases; Chimeric antigen receptor T cells; Chimeric autoantibody receptor T cells.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing interest We declare no competing interests.

MeSH terms

Substances